jj
agre
bn
guidant
deal
pharmaceut
giant
johnson
johnson
ha
agre
to
buy
medic
technolog
firm
guidant
for
bn
â£bn
guidant
is
a
key
produc
of
equip
that
combat
heart
problem
such
a
implant
defibril
and
pacemak
analyst
said
that
the
deal
is
aim
at
offset
johnson
johnson
relianc
on
a
slow
drug
busi
they
also
point
out
that
more
merger
are
like
becaus
the
drug
and
healthcar
industri
are
fragment
and
are
under
pressur
to
cut
cost
a
number
of
johnson
johnson
product
are
face
patent
expir
while
the
compani
is
also
battl
fierc
competit
from
gener
product
meanwhil
demand
for
defibril
which
give
the
heart
a
small
electr
shock
when
an
irregular
heartbeat
or
rhythm
is
detect
is
expect
to
increas
analyst
said
the
move
by
johnson
johnson
ha
been
wide
expect
and
the
firm
will
pay
for
each
guidant
share
more
than
wednesday
close
price
analyst
say
that
u
antitrust
regul
could
forc
the
firm
to
shed
some
overlap
stent
oper
stent
are
tube
that
are
use
to
keep
an
arteri
open
after
it
ha
been
unblock
